Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19

• Status: Recruiting
• Trial end date: 2022-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to assess the safety, tolerability and treatment effect of the orally administered Caspase-1 inhibitor, belnacasan, for the treatment of patients with mild to moderate COVID-19 and to generate proof of concept for future trials.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: MedStar Health

Criteria

Inclusion Criteria:

1. Subject (or legally authorized representative) provides written informed consent prior to the initiation of any study procedures

2. Subject understands and agrees to comply with planned study procedures, including using the diary

3. Subject agrees to the collection of nasopharyngeal swabs and venous blood per protocol

4. Subject is male or non-pregnant female adult ≥18 years of age at time of consent

a. Women with a history of menstruation must agree to use two methods of contraception, at least one of which is highly effective, for the duration of the study as well as to undergo additional pregnancy testing during the study

5. Subject has a laboratory confirmed SARS-CoV-2 infection as determined by RT-PCR assay prior to enrollment

6. Subject has evidence of either mild or moderate COVID-19 illness of less than 7 days from first onset, with minimal baseline symptom severity based on patient-reported FDA scoring system defined as follows:

1. Subject presents with at least two common symptoms of COVID-19 from the following list: Stuffy or runny nose, sore throat, cough, low energy or tiredness, muscle or body ache, headache, chills or shivering, feeling hot or feverish, nausea, vomiting, diarrhea, shortness of breath with exertion (without supplemental oxygen requirement) with a score of 2 or higher, impairment in sense of smell or taste with a score of 1 or higher OR

2. Subject presents with any (i.e., at least one) symptom of COVID-19 as defined above AND clinical evidence of moderate COVID-19 as defined by FDA guidance for industry (such as respiratory rate >20 breaths per minute, heart rate >90 beats per minute, with oxygen saturation >93% on room air at sea level)

7. Subject presents with high-risk for COVID-19-related inflammation determined by at least one comorbidity, including obesity, diabetes, hypertension, stable heart disease, respiratory disease, and/or non-severe fatty liver disease

8. Subject's overall health condition is deemed as suitable to fully and safely participate in this trial as determined by the investigator

Exclusion Criteria:

1. Any clinical signs indicative of severe or critical COVID-19 as defined by FDA guidance for Industry at the time, including SpO2 <93% and/or oxygen requirement

2. Hospitalization for COVID-19, or consideration thereof

3. ICU level of care and/or non-mechanical/mechanical ventilation and/or oxygen supplementation at time of enrollment

4. Pregnant or breast-feeding subjects

5. Subjects who cannot swallow tablets

6. History of any pre-existing organ impairment, such as:

1. Severe kidney disease (known or estimated GFR <30 mL/minute) or on dialysis

2. Uncontrolled, clinically significant heart diseases such as arrhythmias, angina or heart failure as defined by AHA/ACC Grade C and D

3. Chronic respiratory disease requiring supplemental oxygen

4. Moderate and severe hepatic impairment as defined by Child-Pugh scoring Class B and Class C

7. Elevated liver function test (determined by ALT, AST, GGT, or ALP >2x upper limit of normal, and/or total Bilirubin > upper limit of normal)

8. History of malignancy or immunodeficiency within the prior 5 years

9. Acute respiratory illness other than COVID-19

10. Acute bacterial, viral or fungal infection (including HIV, hepatitis B, hepatitis C)

11. While dosed with IP, the taking of prohibited concomitant medication or the ingestion of food that interferes with the IP, including:

1. Non-COVID19-related anti-viral medication such as lopinavir, ritonavir, ribavirin, or interferon-1β

2. Systemically administered immunosuppressive and anti-inflammatory agents, other than background standard of care for COVID-19 at the time

3. Drugs and foods that are potent inhibitors or inducers of CYP3A4 and/or P-gp, as listed in FDA "Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers", including herbal medications such as St. John's Wort within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug

12. Any other diseases or medical conditions or concomitant medications that are deemed as not compatible or appropriate for the subject's ability to fully and safely participate in this trial as determined by the investigator